

**EXTENDED SPECTRUM β -LACTAMASES AMONG ENTEROBACTERIACEAE ISOLATED
FROM CLINICAL SPECIMENS OF A TERTIARY HOSPITAL IN 2014**

ABSTRACT

Extended spectrum beta-lactamase producing *Enterobacteriaceae* has become widespread among hospitals even in the community that poses therapeutic dilemma against certain antimicrobial drugs that limits therapeutic options. This study was conducted to evaluate the prevalence of ESBL producing *Enterobacteriaceae* in a tertiary hospital in Bacolod City and its antibiotic resistance profile for the year 2014. Out of 662 isolates, 125 (18.89%) were found to be ESBL producing and was frequently seen in *Escherichia coli* (4.96%), *Klebsiella pneumoniae* (4.08%) and *Enterobacter aerogenes* (3.36%). Urine was found to be the most common specimen to contain this type of bacteria (7.70%), followed by wounds and abscess (5.14%), and sputum (3.63%). These isolates were also found to be least resistant to amikacin with 10.5% followed by imipenem and meropenem with 17.1% and 15.4% respectively. Furthermore, there was no significant difference with regard to sex ($p=0.051664$) and with significant difference in terms of age ($p=0.11415$).

Keywords: Extended Spectrum β -Lactamases; *Enterobacteriaceae*; tertiary hospital, Bacolod City

INTRODUCTION

Resistance of pathogenic organisms to counteract antibiotics has become a worldwide problem with serious consequences on the treatment of infectious diseases [1]. The heightened use or misuse of antibiotics in human medicine is primarily contributing to the phenomenon. Because of this, there is an

alarming increase of antibiotic resistance in bacteria that cause either community infections or hospital acquired infections. Antimicrobial-resistant infections claim approximately 700,000 lives each year. At least 50,000 of these deaths occur across Europe and the US while many hundreds of thousands more die in other areas of the world [2]. Furthermore, studies estimate that 300 million people are expected to die prematurely because of drug resistance over the next 35 years.

One of the major factors in drug resistance is the production of ESBL. According to Rawat et al. [3], extended-spectrum β -lactamases are a group of plasmid-mediated, diverse, complex and rapidly evolving enzymes that are posing a major therapeutic challenge today in the treatment of hospitalized and community-based patients. ESBLs are a rapidly evolving group of β -lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam but are inhibited by clavulanic acid. Most infections caused by these organisms are described as nosocomial or healthcare related [4], but has started to spread in the community. For the reason of unavailability of local data pertaining to ESBL producing isolates, thus, this study was initiated to give baseline information and to describe the presence of ESBL producing *Enterobacteriaceae* in the area.

MATERIALS AND METHODS

Inclusion / Exclusion Criteria

Data on culture and antibiotic susceptibility tests were collected from the tertiary hospital from January 2014 to December 2014, after the grant of permission from the laboratory supervisor. The hospital where the data was gathered however opted not to point out their identity. Data such as age, sex, specimen source, ID of the isolated *Enterobacteriaceae* and

susceptibility testing were included. No personal data was retrieved from patients in order to preserve confidentiality.

Statistical Analysis

The gathered data were analyzed statistically to determine the frequency, resistance profile and distribution of ESBL producing *Enterobacteriaceae* among patients in terms of age and sex using WHONET version 5.6 software downloaded from World Health Organization website. Age was divided into two categories, adult (19 years old and above) and pediatric (0 - 18 years old) automatically by the WHONET software.

RESULTS

From January 2014 to December 2014, a total of 662 *Enterobacteriaceae* was isolated and identified to genus and species level from different clinical specimens. *E. coli* was the most frequent isolate having a total of 256 (38.67%), followed by *K. pneumoniae* with 107 (16.16%) and *E. aerogenes* with 57 (8.61%). From these 662 isolates, 125 (18.89%) were observed to produce the enzyme ESBL. Noted to be the most numbered producer is *E. coli* (24.8%), followed by *K. pneumoniae* (20.72%) and *E. aerogenes* (3.17%) as shown in Table 1.

Table 1. Frequency of Identified *Enterobacteriaceae* and ESBLs among the Recovered Isolates

Organisms	Number of Isolates	%	ESBL producers	% of ESBL producers
<i>E. coli</i>	256	39	31	12
<i>K. pneumoniae</i>	107	16	27	25
<i>E. aerogenes</i>	57	9	21	37
<i>P. mirabilis</i>	33	5	3	9
<i>P. agglomerans</i>	28	4	7	25

<i>E. gergoviae</i>	24	4	4	17
<i>E. cloacae</i>	22	3	7	32
<i>K. ozaenae</i>	22	3	6	27
<i>P. vulgaris</i>	20	3	1	5
<i>E. hermannii</i>	18	3	4	22
<i>C. koseri</i>	16	2	3	19
<i>H. alvei</i>	16	2	4	25
<i>Salmonella sp.</i>	12	2	0	0
<i>C. freundii</i>	11	2	4	36
<i>E. tarda</i>	11	2	2	18
<i>S. marcescens</i>	4	1	0	0
<i>K. oxytoca</i>	3	0	0	0
<i>P. penneri</i>	1	0	0	0
<i>P. rettgeri</i>	1	0	1	100
TOTAL	662	100	125	19

For the distribution of bacterial isolates and ESBL producers as to the sample source, urine was found to be the major source with 42.60% of the total specimen, followed by wounds and abscess with 29.76%. Out of 125 ESBL producing isolates, it was most frequently observed in urine with 40.8%, followed by wounds and abscess with 27.2%. Table 2 summarizes the specimen wise distribution of ESBL producers.

Table 2: Distribution of ESBL Producers According to Type of Specimen.

Type of Specimen	Number of Isolates	ESBL producers	(%)
Urine	282	51	18
Wound & Abscess	197	34	18

Blood	88	13	15
Sputum& ETA	95	24	25
TOTAL	662	125	17

Table 3: Distribution of Bacteria According to Specimen Source

Organism	Urine	Blood	Sputum & ETA	Wound & Abscess	Total
<i>C. freundii</i>	3	3	2	3	11
<i>C. koseri</i>	4	2	1	9	16
<i>E. tarda</i>	4	2	1	4	11
<i>E. aerogenes</i>	15	3	19	20	57
<i>E. cloacae</i>	7	1	5	9	22
<i>E. gergoviae</i>	2	5	3	14	24
<i>E. coli</i>	151	45	10	50	256
<i>E. hermannii</i>	14	1	1	2	18
<i>H. alvei</i>	6	3	3	4	16
<i>K. oxytoca</i>	1	0	1	1	3
<i>K. ozaenae</i>	12	1	7	2	22
<i>K. pneumoniae</i>	35	9	36	27	107
<i>P. agglomerans</i>	15	0	2	11	28
<i>P. mirabilis</i>	8	0	4	21	33
<i>P. penneri</i>	0	0	0	1	1
<i>P. rettgeri</i>	1	0	0	0	1
<i>P. vulgaris</i>	3	0	0	17	20
<i>Salmonella sp.</i>	0	12	0	0	12
<i>S. marcescens</i>	1	1	0	2	4
TOTAL	282	88	95	197	662

As to the distribution of isolates according to specimen source, *E. coli* was still the most common bacteria isolated from urine, wounds and abscesses, and blood specimens, while *K. pneumoniae*

was frequently found in sputum and ETA. Table 3 shows the frequency of the isolated *Enterobacteriaceae* per specimen.

Table 4: Distribution of the ESBL Producers According to Age and Sex

Organism	Pediatric		Adult	
	Male	Female	Male	Female
<i>C. freundii</i>	1	0	1	2
<i>C. koseri</i>	1	0	0	2
<i>E. tarda</i>	0	0	0	2
<i>E. aerogenes</i>	1	1	8	11
<i>E. cloacae</i>	1	0	3	3
<i>E. gergoviae</i>	0	0	4	0
<i>E. coli</i>	1	2	9	19
<i>E. hermannii</i>	0	0	0	4
<i>H. alvei</i>	0	0	2	2
<i>K. oxytoca</i>	0	0	0	0
<i>K. ozaenae</i>	0	0	3	3
<i>K. pneumoniae</i>	1	1	17	8
<i>P. agglomerans</i>	1	1	4	1
<i>P. mirabilis</i>	0	0	0	3
<i>P. rettgeri</i>	0	0	1	0
<i>P. vulgaris</i>	0	0	1	0
<i>S. marcescens</i>	0	0	0	0
TOTAL	7	5	53	60

The distribution of the ESBL producers according to age and sex, which is shown in Table 4, revealed that the maximum number of ESBL producers were seen in the adult age group and that the prevalence was more among the females (the highest) comprising 48% of the 125 ESBL producing strains than among the males

covering 42% of the total ESBL producing strains. The least prevalence was seen in the last two groups; the pediatric males and pediatric females.

Table 5: Significant Difference of ESBL-positive organisms as to selected variables

Variable	Category	p-value	Interpretation
Age	Pediatric (0-18 yrs old)	0.011415	Significant
	Adult (19 and above)		
Sex	Male	0.051664	Not Significant
	Female		

Based on the gathered data, Trimethoprim/Sulfamethoxazole had the highest resistance with 78.4%, followed by ampicillin/sulbactam and ciprofloxacin with 75% and 74.4% respectively. Amikacin was most effective with 10.5% resistance rate followed by meropenem and imipenem with 15.4% and 17.1%.




Figure 2: Antibiotic resistance rates (%) of ESBL-producers

Out of the total 662 isolates, *E. coli* was noted to be the most common of the said bacteria that produces the enzyme ESBL, followed by *K. pneumoniae* and *Enterobacter species* with frequencies of 24.8%, 21.6% and 16.8% respectively. This is because *Enterobacteriaceae* can harbor plasmid-mediated ESBL genes and both *E. coli* and *K. pneumoniae* are the most common ESBL positive species [5]. These types of isolates that produces the said enzyme is clinically relevant and remains an important cause of cephalosporin therapy failure [6]. This finding, as supported by Ali et al.[7], is accounted to the said organisms' emerging resistance to agents such as extended-spectrum cephalosporins, monobactams, carbapenems and β -lactam- β -lactamase inhibitor combinations through the production of a variety of β -lactamases, alterations in the penicillin-binding proteins, outer membrane permeability and combinations of multiple mechanisms of resistance [8].

In the current study, *E. coli* is noted to be the most prevalent pathogen isolated in wound and abscess, urine and blood taking into consideration that *E. coli* is a member of the human microbiota that can cause several kinds of nosocomial and community acquired infections [9]. *E. coli* is known to invade urothelial cells and form quiescent intracellular bacterial reservoirs [10]. This is followed by *K. pneumoniae* that causes serious respiratory tract infections and is also one of the frequent pathogen causing urinary tract infections [11]. Both *K. pneumoniae* and *E. coli* remain as the major ESBL producing organism worldwide and are recommended to be tested routinely for ESBL production [12]. This data is also at par with the data of Lenhard-Vidal et al. [9] in Brazil, Jabeen et al.[13] in Pakistan and Ghafourian et al. [14] in Iran.

Urine was observed to be the most common specimen source that contains ESBL producing species in this study. This is because recurrence of urinary tract infection is common even for a healthy individual [10] and a common problem of women throughout their lifetimes [15]. Statistically, urinary tract infection is the most common bacterial infection that counts for more than 8 million clinic visits and 1 million emergency department visits each year [16]. Furthermore, urinary tract infection is twice as common among women of all ages compared with men. Females have the highest prevalence of ESBL compared to males because of their short urethra, certain behavioral factors like micturition and sexual activities [15, 17]. Moreover, UTI is also very common both in the community and hospitalized patients that ranks high amongst the most common reasons that compel a patient to seek medical attention [5]. Urinary tract infection can range from asymptomatic bacteriuria, to symptomatic and recurrent to sepsis [16].

As to age group, the maximum number of ESBL producers were seen in the adult age group and that the prevalence was more among the females (the highest) comprising 48% of the 125 ESBL producing strains. ESBLs-producing gram-negative rods were most frequent at latter part of life where they most commonly infect individuals due to exposure to antibiotics and other factors [18]. The least prevalence was seen in the last two groups; the pediatric males and pediatric females. Pediatric males comprise 6% of the total ESBL positive isolates. Out of 125 ESBL positive isolates, only 4% of the pediatric females are found to be ESBL producers. Hence, the pediatric females have the lowest prevalence of ESBL as to this study. According to Paterson and Bonomo [19], the age distribution of β -lactamase and ESBLs producers among the patients showed high prevalence among the

197 adult age group. This may be because old people often become
198 immune-compromised and stand greater chances of coming down with
199 infections. Such infections are of many types but in patients
200 with low immunity they are more difficult to treat. This may
201 explain the relatively high presence of extended spectrum *beta*-
202 *lactamase* producers among the aged.

203
204 The top 5 antibiotics where ESBL-producing Enterobacteriaceae,
205 showed highest resistance to trimethoprim/sulfamethoxazole
206 (78.4), ampicillin/sulbactam (75%) and ciprofloxacin (74.4%). It
207 is not surprising that antibiotic choice for infections with
208 such ESBL-producing organisms is seriously reduced given the
209 ability of such organisms to hydrolyze many β -lactam antibiotics
210 [19]. This result may have been caused by the frequent
211 antibiotic use over long periods of time which in turn, puts
212 selective pressure on bacteria, and causes resistance to spread.
213 Since many antibiotics are used too often or incorrectly, it is
214 expected that resistance spread faster than it would naturally
215 [20]. Additionally, the three aforementioned antibiotics are
216 considered to be the least effective to use as medications in
217 ESBL-producing organisms because a high resistance rate is an
218 indication that the organism is no longer susceptible to the
219 said drug, making treatment ineffective and null.

220
221 Meanwhile, the ESBL-producing organisms were least resistant to
222 amikacin, meropenem, and imipenem. Amikacin had 10.5% resistance
223 rate followed by meropenem with 15.4% resistance rate and
224 imipenem which has 17.1% resistance rate. This is an implication
225 that the organisms in the study were most susceptible to the
226 three aforementioned antibiotics. This finding is also similar
227 to the study of Juayang et al. [8], Maina et al. [6] and Al
228 Muharrmi et al. [21]. Amikacin has good in vitro activity

against ESBL-producing organisms such as *K. pneumoniae* strains [22]. In vitro, the carbapenems have the most consistent activity against ESBL-producing organisms, given their stability to hydrolysis by ESBLs. This implies that ESBLs are generally inactive against the carbapenem antibiotics [19]. With this, Pitout & Laupland [23] and Juayang et al. [8], indicated that carbapenems or amikacin are widely regarded as the drugs of choice for the treatment of severe infections caused by ESBL-producing *Enterobacteriaceae*. Unfortunately however, even though amikacin was noted to be the most effective, it has toxic side effects such as nephrotoxicity and neurotoxicity, making carbapenems and piperacillin/tazobactam as the treatment of choice as of this time [8]. These results are analogous to that of Jabeen et al. [13] which showed results of higher resistance to classes of antibiotics such as aminoglycosides and quinolones and no resistance to carbapenems.

CONCLUSION:

ESBL producing *Enterobacteriaceae* displays high level of antimicrobial resistance that hinders efficacy of cephalosporins and other related drugs, thus, making carbapenem as the drug of choice for treatment. *E. coli* was observed to be the most frequent ESBL producer followed by *K. pneumonia* that are commonly isolated in urine, wound and abscess, and even respiratory specimens that presents mostly in adults. It is therefore imperative that monitoring of ESBL producing organisms among hospitals to evaluate local status, stricter antimicrobial stewardship and for formulation of policies for empiric therapy.

References:

1. Shaikh S, Fatimab J, Shakilb S, Mohd S, Rizvia D and Kamalc MA. *Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment*. Saudi Journal of Biological Sciences. (2014). Volume 22 (1): pp. 90-101.
2. O' Neill J. *The Review on Antimicrobial Resistance: 2014; Tackling drug-resistant infections globally*. Available: http://amrreview.org/sites/default/files/AMR%20Review%20Paper%20%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (*Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations; 2014*. Retrieved September 17, 2015).
3. Rawat D and Nair D. *Extended-spectrum β -lactamases in Gram Negative Bacteria*. Journal of Global Infectious Diseases. (2010). Volume 2 (3): pp. 263-274.
4. Barakzahi M, Hormozi B, Rashki A and Ghalehnoo Z. *Prevalence of Extended Spectrum β -lactamase in Klebsiella pneumoniae Isolates in a Teaching Hospital of Zahedan City, Iran*. (2014). Avicenna Journal of Clinical Microbiology and Infection. Volume 1 (3): pp. 1-4.
5. Mekki A, Nur Hassan A and Elsayed D. *Extended Spectrum beta lactamases among multidrug resistant Escherechia coli and Klebsiella species causing urinary trac infections in Khartoum*. (2010). Journal of Bacteriology Research. Volume 2 (3): pp. 18-21.
6. Maina D, Makau P, Nyerere A and Revathi G. *Antimicrobial resistance patterns in extended- spectrum β -lactamase producing Escherechia coli and Klebsiella pneumoniae*

- isolates in a private tertiary hospital, Kenya. (2013). Microbiology Discovery. Volume 2052 (6182): pp. 1-5.
7. Ali AM, Raffi S and Qureshi AH. *Frequency of Extended Spectrum Beta-Lactamase producing gram negative bacilli among clinical isolates at clinical laboratories of Army Medical College, Rawalpindi.* (2002). Journal of Ayub Medical College, Abbottabad. Volume 16(1): pp. 35-7.
8. Juayang A, Maestral D, Delos Reyes G, Acosido M and Gallega C. *Review on the Antimicrobial Resistance of Pathogens from Tracheal and Endotracheal Aspirates of Patients with Clinical Manifestations of Pneumonia in Bacolod City in 2013.* (2015). International Journal of Bacteriology. Volume 2015 (942509): 5 pages.
9. Lenhard-Vidal A, Cardoso R, De Padua R and Siqueira V. *High prevalence rate of extended-spectrum beta-lactamases (ESBL) among Enterobacteriaceae in a small Brazilian public hospital.* 2011. Brazilian Journal of Pharmaceutical Sciences. Volume 47 (4): pp. 701-705.
10. Hickling D and Nitti V. *Management of Recurrent Urinary Tract Infections in Healthy Adult Women.* (2013). Reviews in Urology. Volume 15 (2): pp. 41-48.
11. Barakzahi M, Hormozi B, Rashki A and Ghalehnoo Z. *Prevalence of Extended Spectrum β -lactamase in Klebsiella pneumoniae Isolates in a Teaching Hospital of Zahedan City, Iran.* (2014). Avicenna Journal of Clinical Microbiology and Infection. Volume 1 (3): pp. 1-4.
12. Sarojamma V and Ramakrishna V. *Prevalence of ESBL-Producing Klebsiella pneumoniae Isolates in Tertiary Care Hospital.* (2011). International Scholarly Research Network Microbiology. Volume 2011 (318348): 5 pages.
13. Jabeen K, Zafar A and Hasa R. *Frequency and sensitivity pattern of Extended Spectrum Beta Lactamase producing*

- isolates in a tertiary care hospital laboratory of
Pakistan. (2005). J Pak Med Association. Volume 55 (10):
pp. 436-439.
14. Ghafourian S, Sekawi Z, Neela V, Khosravi A, Rahbar M and
Sadeghifard N. *Incidence of extended-Spectrum beta-
lactamase-producing Klebsiella pneumoniae in patients with
urinary tract infection.* (2012). Sao Paulo Medical Journal,
Volume 130 (1): pp. 37-43.
15. Grover ML, Bracamonte JD, Kanodia AK, Edwards FD and Weaver
AL. *Urinary Tract Infection in Women Over the Age of 65: Is
Age Alone a Marker of Complication?.*(2009). Journal of the
American Board of Family Medicine. Volume 22 (3): pp. 266-
271.
16. Mody L and Juthani-Mehta M. *Urinary Tract Infections in
Older Women.* (2014). HHS Public Access Author Manuscript.
Volume 311 (8): pp. 844-854.
17. Hotchandani R and Aggarwal K. *Urinary Tract Infections in
Women.* (2012). Indian Journal of Clinical Practice. Volume
23 (4): pp. 187-192.
18. Mumtaz S, Ahmad M, Aftab I, Akhtar N, ul Hassan M and Hamid
A. *Extended spectrum beta-lactamases in enteric gram-
negative bacilli: related to age and gender.* (2007).
Journal of Ayub Medical College, Abbottabad. Volume 19 (4):
pp. 104-111.
19. Paterson DL and Bonomo RA. *Extended-Spectrum β -Lactamases:
a Clinical Update.* (2005). Clinical Microbiology Reviews.
Volume 18 (4): pp. 657-686.
20. Charpentier E and Tuomanen E. *Mechanisms of antibiotic
resistance and tolerance in Streptococcus pneumoniae.*
(2000). Microbes and Infection, Volume 2 (15): pp. 1855-
1864.

21. Al Muharrmi Z, Rafay A, Balkhair A, Al-Tamemi S, Al Mawali A and Al Sadiri H. *Extended-spectrum Beta-lactamase Orthopedic Wound Infections in Nigeria*. (2008). Sultan Qaboos University Medical Journal. Volume 8 (2): pp. 171-177.
22. Anderlik P, Filetoh Z, Máthé A, Szabó D, Rokusz L and Rozgonyi F. *In Vitro and In Vivo Activities of Amikacin, Cefepime, Amikacin plus Cefepime, and Imipenem against an SHV-5 Extended-Spectrum β -Lactamase-Producing Klebsiella pneumoniae Strain*. (2001). Antimicrobial Agents and Chemotherapy. Volume 45 (4): pp. 1287-1291.
23. Pitout J and Laupland K. *Extended-spectrum β -lactamase-producing Enterobacteriaceae: an emerging public-health concern*. (2008). The Lancet Infectious Diseases. Volume 8 (3): pp. 159-166.